| Gem City Healthcare And Rehabilitation Center | |
| 323 Forest Avenue, Dayton, Ohio 45405 | |
| (937) 224-0793 | |
| Name | Gem City Healthcare And Rehabilitation Center |
|---|---|
| Location | 323 Forest Avenue, Dayton, Ohio |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 87 |
| Occupancy Rate | 44.37% |
| Medicare ID (CCN) | 365981 |
| Legal Business Name | Gem City Healthcare And Rehabilitation Center Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1194324350 |
| Organization Name | GEM CITY HEALTHCARE AND REHABILITATION CENTER LLC |
| Address | 323 Forest Ave, Dayton, OH 45405 |
| Phone Number | 718-942-3483 |
News Archive
Idera Pharmaceuticals, Inc. today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis.
Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced the publication of an overview of lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Atherosclerosis, the official journal of the European Atherosclerosis Society.
In an independent report published today, an analysis from over 100 experts finds the benefits of protecting 30% of the planet outweigh the costs by a factor of at least 5:1.
On Tuesday, South African Health Minister Aaron Motsoaledi cautioned that Africa might be hit harder by H1N1 (swine) flu than other parts of the world, the Associated Press reports (8/11).
› Verified 6 days ago
| NPI Number | 1366558157 |
| Organization Name | HARBORSIDE OF DAYTON LIMITED PARTNERSHIP |
| Doing Business As | FOREST VIEW CENTER |
| Address | 323 Forest Ave, Dayton, OH 45405 |
| Phone Number | 937-224-0793 |
News Archive
Idera Pharmaceuticals, Inc. today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis.
Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced the publication of an overview of lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Atherosclerosis, the official journal of the European Atherosclerosis Society.
In an independent report published today, an analysis from over 100 experts finds the benefits of protecting 30% of the planet outweigh the costs by a factor of at least 5:1.
On Tuesday, South African Health Minister Aaron Motsoaledi cautioned that Africa might be hit harder by H1N1 (swine) flu than other parts of the world, the Associated Press reports (8/11).
› Verified 6 days ago
| NPI Number | 1912488693 |
| Organization Name | FORESTVIEW OPCO LLC |
| Address | 323 Forest Ave, Dayton, OH 45405 |
| Phone Number | 937-224-0793 |
News Archive
Idera Pharmaceuticals, Inc. today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis.
Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced the publication of an overview of lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Atherosclerosis, the official journal of the European Atherosclerosis Society.
In an independent report published today, an analysis from over 100 experts finds the benefits of protecting 30% of the planet outweigh the costs by a factor of at least 5:1.
On Tuesday, South African Health Minister Aaron Motsoaledi cautioned that Africa might be hit harder by H1N1 (swine) flu than other parts of the world, the Associated Press reports (8/11).
› Verified 6 days ago
| NPI Number | 1982366282 |
| Organization Name | AVENTURA AT GEM CITY LLC |
| Address | 323 Forest Ave, Dayton, OH 45405 |
| Phone Number | 937-224-0793 |
News Archive
Idera Pharmaceuticals, Inc. today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis.
Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced the publication of an overview of lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Atherosclerosis, the official journal of the European Atherosclerosis Society.
In an independent report published today, an analysis from over 100 experts finds the benefits of protecting 30% of the planet outweigh the costs by a factor of at least 5:1.
On Tuesday, South African Health Minister Aaron Motsoaledi cautioned that Africa might be hit harder by H1N1 (swine) flu than other parts of the world, the Associated Press reports (8/11).
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Idera Pharmaceuticals, Inc. today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis.
Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced the publication of an overview of lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Atherosclerosis, the official journal of the European Atherosclerosis Society.
In an independent report published today, an analysis from over 100 experts finds the benefits of protecting 30% of the planet outweigh the costs by a factor of at least 5:1.
On Tuesday, South African Health Minister Aaron Motsoaledi cautioned that Africa might be hit harder by H1N1 (swine) flu than other parts of the world, the Associated Press reports (8/11).
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 30.67 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 3.03 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 17.27 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.91 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 38.89 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.37 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 96.63 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 17.89 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 94.31 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 27.02 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 20.96 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 8.24 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.01 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 54.64 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 70.93 | 82.93 |
News Archive
Idera Pharmaceuticals, Inc. today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis.
Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced the publication of an overview of lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Atherosclerosis, the official journal of the European Atherosclerosis Society.
In an independent report published today, an analysis from over 100 experts finds the benefits of protecting 30% of the planet outweigh the costs by a factor of at least 5:1.
On Tuesday, South African Health Minister Aaron Motsoaledi cautioned that Africa might be hit harder by H1N1 (swine) flu than other parts of the world, the Associated Press reports (8/11).
› Verified 6 days ago
Garden Court Nursing And Rehabilitation Center Location: 4911 Covenant House Drive, Dayton, Ohio 45426 Phone: (937) 837-2651 | |
Promedica Skilled Nursing And Rehab Beavercreek Location: 1974 North Fairfield Road, Dayton, Ohio 45432 Phone: (937) 429-1106 | |